The benefit of running clinical trials in Asia-Pacific for biotech companies
According to Frost & Sullivan, the CRO market is forecast to grow to US$ 71.7billion by 2024 (+8% CAGR 19-24F).…
Accelerating Clinical Trials
In association with Accelerating Clinical Trials
Is Australia the future for successful first-in-human clinical studies?
The number of biotech-sponsored clinical trials in Australia has grown by more than +10% on average each year between 2017…
Latest News
View More
Data shows majority of Australian sites are open for clinical trial activity
Novotech, the Asia-Pacific CRO, has published data detailing the current status of clinical trials in the Asia-Pacific region during the global COVID-19 crisis. According to…
Managing the Covid-19 outbreak: Lessons learnt from South Korea
Due to its geographic proximity with China, South Korea was one of the first locations hit with the Covid-19 viral infections. But the country has…
Clinical trials data report for Asia-Pacific: Frost & Sullivan collaborates with Novotech
Business consulting firm Frost & Sullivan and Asia-Pacific CRO specialist Novotech published a report summarising the main trends and developments…
Novotech case study: Global reach through CRO partnership for a phase 2 oncology trial
The alliance of regional specialists can provide the best of all worlds: global coverage, regional specialisation and mid-sized CRO flexibility.…
Case studies in accelerating clinical trials in oncology
Clinical development in oncology and immunotherapies has accelerated dramatically over the past few years. As of December 2019, over 6,000…
Regulatory requirements for clinical trials: A comparison of Australia and the US
The regulatory environment in Australia and New Zealand offers a significant strategic opportunity for international biotech companies wanting a fast…